[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented ...

The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomideIn a pivotal PPMS study ...